Thursday, 6 October 2011
The common company of Galenica and Fresenius Medical Care - Vifor Fresenius Medical Care Renal Pharma Ltd. (Vifor FMC Renal Pharma) – has received approval from the responsible antitrust authorities. Achievement of this important milestone allows for Vifor FMC Renal Pharma to proceed with the targeted expansion of its operation in Europe and other countries after the formal closing in November, 2011.
_Vifor FMC Renal Pharma develops and commercialises innovative and high quality therapies to improve the life of patients suffering from Chronic Kidney Disease (CKD) worldwide. The company was founded at the end of 2010 and is owned 55 percent by Galenica and 45 percent by Fresenius Medical Care.
_Given the approval of the responsible antitrust authorities, Galenica’s company Vifor Pharma will now transfer the nephrology marketing and sales rights to Ferinject® and Venofer® as well as all rights to PA21 for Europe and other regions to Vifor FMC Renal Pharma. Marketing and distribution on behalf of Vifor FMC Renal Pharma will be conducted either by Vifor Pharma, Fresenius Medical Care or a third party depending on the organisational structure of the partners in each country. The collaboration on PA21 with Kissei Pharmaceutical Co. in Japan, announced in September 2010, will continue.
_Financial terms of the agreement will not be disclosed.
Galenica is a diversified Group active throughout the healthcare market which, among other activities, develops, manufactures and markets pharmaceutical products, runs pharmacies, provides logistical and database services and sets up networks. With its two Business units Vifor Pharma and Galenica Santé, the Galenica Group enjoys a leading position in all its core business activities. A large part of the Group’s income is generated by international operations. Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALN, security number 1,553,646).
_Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALN).
_Vifor Pharma, a company of the Galenica Group, is a world leader in the discovery, development, manufacturing and marketing of pharmaceutical products for the treatment of iron deficiency. The company also offers a diversified portfolio of prescription medicines as well as over-the-counter (OTC) products. Vifor Pharma, headquartered in Zurich, Switzerland, has an increasingly global presence and a broad network of affiliates and partners around the world.
Venofer® (iron sucrose injection) is the leading intravenous (i.v.) iron product for the treatment of iron deficiency anaemia in renal patients. Ferinject® (US brand name Injectafer®, ferric carboxymaltose) is a novel i.v. iron replacement therapy, also a non-dextran iron, that can be rapidly administered in large i.v. doses. Ferinject® is currently registered for use in 35 countries worldwide. PA21 is a novel iron based phosphate binder which is currently in development phase III. Filing is expected in 2012.
_For more information please visit the company’s website at www.viforpharma.com.
_Fresenius Medical Care is the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 2 million individuals worldwide. Through its network of 2,838 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to 225,909 patients around the globe. Fresenius Medical Care also is the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products.
Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME, FME3) and the New York
Stock Exchange (FMS, FMS/P).
_For more information please visit the company’s website at www.fmc-ag.com
Thursday, 15 December 2011
Monday, 12 December 2011
Tuesday, 15 November 2011
Monday, 14 November 2011
Head of Corporate Communications